Effects of teneligliptin on glycemic control and bone metabolic markers in diabetic patients undergoing hemodialysis

Trial Profile

Effects of teneligliptin on glycemic control and bone metabolic markers in diabetic patients undergoing hemodialysis

Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Nov 2014

At a glance

  • Drugs Teneligliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Nov 2014 Status changed from recruiting to completed according to University Hospital Medical Information Network-Japan record.
    • 27 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top